Janus Henderson Group PLC Buys 282,985 Shares of Vaxcyte, Inc. $PCVX

Janus Henderson Group PLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 2.2% during the fourth quarter, HoldingsChannel reports. The firm owned 13,387,188 shares of the company’s stock after acquiring an additional 282,985 shares during the quarter. Janus Henderson Group PLC owned approximately 0.10% of Vaxcyte worth $617,731,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Vaxcyte by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 12,320,453 shares of the company’s stock valued at $443,783,000 after acquiring an additional 323,368 shares during the period. Wellington Management Group LLP raised its stake in Vaxcyte by 1.6% in the 3rd quarter. Wellington Management Group LLP now owns 5,032,771 shares of the company’s stock valued at $181,280,000 after acquiring an additional 77,967 shares during the period. State Street Corp raised its stake in Vaxcyte by 4.1% in the 4th quarter. State Street Corp now owns 4,980,005 shares of the company’s stock valued at $229,777,000 after acquiring an additional 194,116 shares during the period. Paradigm Biocapital Advisors LP raised its stake in Vaxcyte by 7.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock valued at $187,698,000 after acquiring an additional 283,265 shares during the period. Finally, Westfield Capital Management Co. LP raised its stake in Vaxcyte by 21.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock valued at $134,452,000 after acquiring an additional 663,817 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

PCVX stock opened at $50.67 on Thursday. The stock has a market capitalization of $7.32 billion, a price-to-earnings ratio of -7.36 and a beta of 1.24. The business’s fifty day moving average price is $53.74 and its two-hundred day moving average price is $52.69. Vaxcyte, Inc. has a fifty-two week low of $29.08 and a fifty-two week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the company posted ($1.04) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -7.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PCVX. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. BTIG Research increased their price target on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and an average target price of $86.00.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total transaction of $180,000.00. Following the transaction, the chief accounting officer owned 28,975 shares in the company, valued at $1,738,500. This trade represents a 9.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the transaction, the chief operating officer owned 158,494 shares in the company, valued at $7,848,622.88. The trade was a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,500 shares of company stock worth $419,288 in the last quarter. Company insiders own 3.30% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.